Shopping Cart 0
Cart Subtotal
AED 0

ProMetic Life Sciences Inc (PLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

ProMetic Life Sciences Inc (ProMetic) is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies. The company develops drug candidates based on its two drug discovery platforms: small molecule therapeutics (PSMT) and plasma-derived therapeutics platforms. The company owns research and development facilities in the UK, the US and Canada and has manufacturing facilities in Canada and the Isle of Man. The company conducts business development activities in the US, Europe and Asia. ProMetic is headquartered in Laval, Quebec, Canada.

ProMetic Life Sciences Inc (PLI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14

Partnerships 15

Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15

ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16

ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17

ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18

ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19

ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20

Licensing Agreements 21

ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22

BL&H Enters into Licensing Agreement with Telesta Therapeutics 23

ProMetic Life Sciences Enters into Licensing Agreement with Generium 24

ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25

ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27

Equity Offering 29

Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29

Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31

ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32

ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33

ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34

Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39

Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41

ProMetic Life Sciences Completes Private Placement Of Shares For USD 23 Million 43

Bioniche Life Sciences Completes Private Placement Of Units For USD 9.4 Million 45

ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47

ProMetic Life Sciences Completes Private Placement Of Shares For USD 1 Million 48

Debt Offering 49

ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49

Acquisition 50

ProMetic Life Sciences Acquires Telesta Therapeutics 50

ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52

ProMetic Life Sciences Inc-Key Competitors 53

ProMetic Life Sciences Inc-Key Employees 54

ProMetic Life Sciences Inc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 57

Financial Announcements 57

Aug 14, 2018: Prometic Life Sciences announces second quarter 2018 financial results 57

May 15, 2018: Prometic Announces 2018 first quarter financial results 59

Mar 28, 2018: Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities 61

Nov 13, 2017: Prometic Reports 2017 Third Quarter Highlights and Financial Results 66

Aug 14, 2017: Prometic Reports 2017 Second Quarter Highlights and Financial Results 68

May 15, 2017: Prometic Reports 2017 First Quarter Highlights and Financial Results 70

Mar 30, 2017: Prometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results 72

Corporate Communications 75

Apr 03, 2018: Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer 75

Product News 76

10/20/2017: Prometic Presents In Vivo Data for PBI-4547 at American Association for the Study of Liver Diseases (AASLD) Meeting 76

06/12/2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 77

05/08/2017: Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference 78

05/08/2017: Prometic to Present New Data on PBI-4425 at the American Thoracic Society's 2017 International Conference 79

Product Approvals 80

Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins 80

Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC) 81

Aug 29, 2017: Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy 82

Jul 11, 2017: Prometic Announces Positive Long Term Clinical Data on Ryplazym in Plasminogen Congenital Deficiency and Provides Regulatory Update 83

Apr 05, 2017: Prometic completes the filing of its plasminogen Biologics License Application with the U.S. FDA 84

Other Significant Developments 85

Feb 20, 2018: Prometic Announces Realignment of its Clinical Program Priorities for 2018 85

May 10, 2017: Prometic reports its 2017 annual and special meeting of shareholders highlights 87

Apr 07, 2017: Prometic Receives USD 9.5 Million Purchase Order From Multinational Client 89

Appendix 90

Methodology 90

About GlobalData 90

Contact Us 90

Disclaimer 90


List Of Figure

List of Figures

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14

Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15

ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16

ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17

ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18

ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19

ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20

ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22

BL&H Enters into Licensing Agreement with Telesta Therapeutics 23

ProMetic Life Sciences Enters into Licensing Agreement with Generium 24

ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25

ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27

Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29

Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31

ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32

ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33

ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34

Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39

Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41

ProMetic Life Sciences Completes Private Placement Of Shares For USD 23 Million 43

Bioniche Life Sciences Completes Private Placement Of Units For USD 9.4 Million 45

ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47

ProMetic Life Sciences Completes Private Placement Of Shares For USD 1 Million 48

ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49

ProMetic Life Sciences Acquires Telesta Therapeutics 50

ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52

ProMetic Life Sciences Inc, Key Competitors 53

ProMetic Life Sciences Inc, Key Employees 54

ProMetic Life Sciences Inc, Other Locations 55

ProMetic Life Sciences Inc, Subsidiaries 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ProMetic Life Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ProMetic Life Sciences Inc (ProMetic) is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies. The company develops drug candidates based on its two drug discovery platforms: small molecule therapeutics (PSMT) and plasma-derived therapeutics platforms. The company owns research and development facilities in the UK, the US and Canada and has manufacturing facilities in Canada and the Isle of Man. The company conducts business development activities in the US, Europe and Asia. ProMetic is headquartered in Laval, Quebec, Canada.

ProMetic Life Sciences Inc (PLI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14

Partnerships 15

Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15

ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16

ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17

ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18

ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19

ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20

Licensing Agreements 21

ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22

BL&H Enters into Licensing Agreement with Telesta Therapeutics 23

ProMetic Life Sciences Enters into Licensing Agreement with Generium 24

ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25

ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27

Equity Offering 29

Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29

Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31

ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32

ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33

ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34

Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39

Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41

ProMetic Life Sciences Completes Private Placement Of Shares For USD 23 Million 43

Bioniche Life Sciences Completes Private Placement Of Units For USD 9.4 Million 45

ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47

ProMetic Life Sciences Completes Private Placement Of Shares For USD 1 Million 48

Debt Offering 49

ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49

Acquisition 50

ProMetic Life Sciences Acquires Telesta Therapeutics 50

ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52

ProMetic Life Sciences Inc-Key Competitors 53

ProMetic Life Sciences Inc-Key Employees 54

ProMetic Life Sciences Inc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 57

Financial Announcements 57

Aug 14, 2018: Prometic Life Sciences announces second quarter 2018 financial results 57

May 15, 2018: Prometic Announces 2018 first quarter financial results 59

Mar 28, 2018: Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities 61

Nov 13, 2017: Prometic Reports 2017 Third Quarter Highlights and Financial Results 66

Aug 14, 2017: Prometic Reports 2017 Second Quarter Highlights and Financial Results 68

May 15, 2017: Prometic Reports 2017 First Quarter Highlights and Financial Results 70

Mar 30, 2017: Prometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results 72

Corporate Communications 75

Apr 03, 2018: Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer 75

Product News 76

10/20/2017: Prometic Presents In Vivo Data for PBI-4547 at American Association for the Study of Liver Diseases (AASLD) Meeting 76

06/12/2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 77

05/08/2017: Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference 78

05/08/2017: Prometic to Present New Data on PBI-4425 at the American Thoracic Society's 2017 International Conference 79

Product Approvals 80

Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins 80

Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC) 81

Aug 29, 2017: Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy 82

Jul 11, 2017: Prometic Announces Positive Long Term Clinical Data on Ryplazym in Plasminogen Congenital Deficiency and Provides Regulatory Update 83

Apr 05, 2017: Prometic completes the filing of its plasminogen Biologics License Application with the U.S. FDA 84

Other Significant Developments 85

Feb 20, 2018: Prometic Announces Realignment of its Clinical Program Priorities for 2018 85

May 10, 2017: Prometic reports its 2017 annual and special meeting of shareholders highlights 87

Apr 07, 2017: Prometic Receives USD 9.5 Million Purchase Order From Multinational Client 89

Appendix 90

Methodology 90

About GlobalData 90

Contact Us 90

Disclaimer 90


List Of Figure

List of Figures

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

ProMetic Life Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10

ProMetic Life Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 14

Prometic Life Sciences to Form Joint Venture with Shenzhen Royal Asset Management 15

ProMetic Life Sciences Enters into Agreement with ProThera Biologics 16

ProMetic BioSciences Enters Into Co-Development Agreement With Pharma Company 17

ProMetic Life Sciences Enters Into Co-Marketing Agreement With Sartorius Stedim Biotech 18

ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 19

ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 20

ProMetic Life Sciences Enters into Licensing Agreement with Omnio 21

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 22

BL&H Enters into Licensing Agreement with Telesta Therapeutics 23

ProMetic Life Sciences Enters into Licensing Agreement with Generium 24

ProMetic Life Sciences Enters Into Licensing Agreement With Shenzhen Hepalink Pharma 25

ProMetic Life Sciences Enters Into Licensing Agreement For Its Affinity Resin Technology 26

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 27

Prometic Life Sciences Raises USD40.2 Million in Public Offering of Shares 29

Prometic Life Sciences Raises USD6.5 Million in Private Placement of Shares 31

ProMetic Life Sciences Raises USD16 Million in Private Placement of Shares upon Exercise of Warrants 32

ProMetic Life Sciences Raises USD3 Million in Private Placement of Shares 33

ProMetic Life Sciences Raises USD47.8 Million in Public Offering of Shares 34

Telesta Therapeutics Raises USD28.3 Million in Private Placement of Shares 36

Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 37

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment Option for USD7.5 Million Bought Deal Public Offering of Shares 38

ProMetic Life Sciences Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 39

Bioniche Life Sciences Raises USD5.2 Million in Public Offering of Units 41

ProMetic Life Sciences Completes Private Placement Of Shares For USD 23 Million 43

Bioniche Life Sciences Completes Private Placement Of Units For USD 9.4 Million 45

ProMetic Life Sciences Raises USD10 Million in Pivate Placement Of Shares 47

ProMetic Life Sciences Completes Private Placement Of Shares For USD 1 Million 48

ProMetic Life Sciences Raises USD30 Million in Private Placement of 8% Notes Due 2022 49

ProMetic Life Sciences Acquires Telesta Therapeutics 50

ProMetic Life Sciences Acquires Additional Stake In NantPro BioSciences 52

ProMetic Life Sciences Inc, Key Competitors 53

ProMetic Life Sciences Inc, Key Employees 54

ProMetic Life Sciences Inc, Other Locations 55

ProMetic Life Sciences Inc, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ProMetic Life Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.